TRAM1

Across TCGA pan-cancer cohorts, TRAM1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TRAM1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRAM1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TRAM1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where TRAM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.931	0.378	.005	28	view →
CCRCC	OS	Tertile	All	0.739	0.940	.006	23	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	19	view →
LSCC	DFS	Median	II,III,IV	0.534	0.832	.003	17	view →
HNSC	DFS	Quartile	All	0.859	0.620	.012	15	view →
UCEC	DFS	Tertile	All	0.740	0.948	.020	8	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TRAM1–LUAD (OS)

Open the LUAD breakdown →